Roivant Sciences is seeking FDA decisions regarding its registrational trial for LPP, which is ongoing.
2 reports, 1 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Roivant Sciences is seeking FDA decisions regarding its registrational trial for LPP, which is ongoing.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Roivant Sciences (United States)
company in New York, United States
Nothing else this week.
-
LPP
Polish company
Nothing else this week.
- FDA
Related events
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Roivant Sciences identifies a potential market for its successful drug candidate in Europe.